F m Investments LLC Increases Position in ANI Pharmaceuticals, Inc. $ANIP

F m Investments LLC increased its stake in ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) by 21.0% in the 4th quarter, Holdings Channel reports. The fund owned 67,803 shares of the specialty pharmaceutical company’s stock after buying an additional 11,753 shares during the quarter. F m Investments LLC’s holdings in ANI Pharmaceuticals were worth $5,352,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. Divisadero Street Capital Management LP purchased a new position in ANI Pharmaceuticals in the third quarter worth $21,454,000. Campbell & CO Investment Adviser LLC purchased a new position in ANI Pharmaceuticals in the third quarter worth $1,597,000. Apis Capital Advisors LLC grew its position in ANI Pharmaceuticals by 28.1% in the third quarter. Apis Capital Advisors LLC now owns 164,000 shares of the specialty pharmaceutical company’s stock worth $15,022,000 after acquiring an additional 36,000 shares in the last quarter. Decker Retirement Planning Inc. grew its position in ANI Pharmaceuticals by 76,862.5% in the third quarter. Decker Retirement Planning Inc. now owns 36,942 shares of the specialty pharmaceutical company’s stock worth $3,384,000 after acquiring an additional 36,894 shares in the last quarter. Finally, SG Americas Securities LLC grew its position in ANI Pharmaceuticals by 791.1% in the third quarter. SG Americas Securities LLC now owns 22,847 shares of the specialty pharmaceutical company’s stock worth $2,093,000 after acquiring an additional 20,283 shares in the last quarter. 76.05% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

Several analysts have issued reports on the stock. Zacks Research upgraded shares of ANI Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, April 15th. Guggenheim upped their price target on shares of ANI Pharmaceuticals from $115.00 to $124.00 and gave the company a “buy” rating in a research report on Friday, January 16th. Finally, Wall Street Zen upgraded shares of ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday. One research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $107.33.

Key Headlines Impacting ANI Pharmaceuticals

Here are the key news stories impacting ANI Pharmaceuticals this week:

• Positive Sentiment: ANI Pharmaceuticals beat Wall Street expectations on both earnings and revenue, reporting $2.05 EPS versus $1.28 expected and revenue of $237.46 million versus $207.63 million expected. The company also said quarterly revenue rose 20.5% year over year, signaling solid underlying growth. Article Title
• Positive Sentiment: The company raised its FY 2026 EPS guidance to $9.19-$9.69, above the consensus estimate of $8.79, which suggests management sees stronger profitability ahead. Article Title
• Neutral Sentiment: Investors are also parsing the earnings call transcript and presentation for details on the company’s growth drivers and updated strategy, but the main stock catalyst today is the beat-and-raise quarter. Article Title
• Neutral Sentiment: ANI also issued revenue guidance around $1.1 billion for FY 2026, roughly in line with expectations, so the revenue outlook appears stable rather than a fresh upside surprise. Article Title

Insider Activity at ANI Pharmaceuticals

In other news, SVP Ori Gutwerg sold 2,060 shares of the stock in a transaction dated Tuesday, March 3rd. The shares were sold at an average price of $76.50, for a total transaction of $157,590.00. Following the completion of the sale, the senior vice president directly owned 84,782 shares in the company, valued at approximately $6,485,823. This represents a 2.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Christopher Mutz sold 3,162 shares of the stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $71.64, for a total transaction of $226,525.68. Following the sale, the insider owned 91,309 shares of the company’s stock, valued at approximately $6,541,376.76. This represents a 3.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 27,860 shares of company stock valued at $2,111,581 in the last quarter. 8.10% of the stock is currently owned by company insiders.

ANI Pharmaceuticals Stock Performance

NASDAQ ANIP opened at $81.86 on Friday. The company has a 50-day simple moving average of $76.82 and a two-hundred day simple moving average of $81.01. The company has a quick ratio of 2.19, a current ratio of 2.71 and a debt-to-equity ratio of 1.11. ANI Pharmaceuticals, Inc. has a 12-month low of $56.71 and a 12-month high of $99.50. The firm has a market cap of $1.83 billion, a price-to-earnings ratio of 24.36 and a beta of 0.46.

ANI Pharmaceuticals (NASDAQ:ANIP) last posted its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.28 by $0.77. The business had revenue of $237.46 million during the quarter, compared to analyst estimates of $207.63 million. ANI Pharmaceuticals had a net margin of 8.87% and a return on equity of 27.97%. The company’s revenue was up 20.5% on a year-over-year basis. During the same period in the prior year, the business posted $1.70 earnings per share. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities analysts forecast that ANI Pharmaceuticals, Inc. will post 7.64 EPS for the current year.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.